Ozmosi | FPT-155 Drug Profile
Drug Search Results
Using advanced filters...
Advanced Search [+]

FPT-155

Alternative Names: fpt-155, fpt 155, fpt155
Clinical Status: Inactive
Latest Update: 2025-01-23
Latest Update Note: Clinical Trial Update

Product Description

Amgen is developing FPT-155 as a treatment for advanced solid tumors. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT04074759)

Mechanisms of Action: CD80 Cleaver

Novel Mechanism: Yes

Modality: Fusion Protein

Route of Administration: Intravenous

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Amgen
Company Location: Western America
Company Founding Year: 1980
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Phase 1: Oncology Solid Tumor Unspecified

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

ACTRN12618001955202

ACTRN12618001955202

P1

Terminated

Oncology Solid Tumor Unspecified

2021-04-29

2026-02-15

Treatments

NCT04074759

FPT155-001

P1

Terminated

Oncology Solid Tumor Unspecified

2021-08-10

50%

2025-01-24